Fengting Yan, MD
I am Fengting Yan, currently a medical oncologist focusing on women's cancer at True Family Women Cancer Center at Swedish Cancer Institute in Seattle. I was trained at the Fred Hutch Cancer Research Center/University of Washington for my hematology/oncology fellowship. My career goal is to translate my research from bench to bedside to improve women health. I have been interested in translational research in women cancer and public education in women health. My interest comes from my background in clinical training in Ob & Gyn in China, years of public education in women health through internet and TV talk shows, Internal medicine residency training and Hematology-Oncology fellowship training in the US, as well as extensive basic lab research training as a post-doctoral researcher. My primary research interest has been to identify oncogenic markers and design inhibitors of these markers for developing new drugs to treat cancer patients, and to deliver updated health related education to women.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:PfizerTopic:The Best of Hematology and Breast Cancer 2025Date added:10/08/2021Date updated:10/02/2024Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstrazenecaTopic:The Best of Hematology and Breast Cancer 2025Date added:10/02/2024Date updated:10/02/2024Relationship end date:12/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GileadTopic:The Best of Hematology and Breast Cancer 2025Date added:10/02/2024Date updated:10/02/2024Relationship end date:12/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Eli LillyTopic:The Best of Hematology and Breast Cancer 2025Date added:10/02/2024Date updated:10/02/2024Relationship end date:12/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:MerckTopic:The Best of Hematology and Breast Cancer 2025Date added:10/02/2024Date updated:10/02/2024Relationship end date:12/31/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:DaiichiTopic:The Best of Hematology and Breast Cancer 2025Date added:10/02/2024Date updated:10/02/2024Relationship end date:12/31/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:GenentechTopic:The Best of Hematology and Breast Cancer 2025Date added:10/02/2024Date updated:10/02/2024Relationship end date:12/31/2025